Pharmacokinetic Study of AVI-4065 in Cerebral Spinal Fluid Among Healthy Adult Males Following Subcutaneous Administration.
Phase of Trial: Phase I
Latest Information Update: 02 Aug 2012
At a glance
- Drugs AVI 4065 (Primary)
- Indications Hepatitis C
- Focus Pharmacokinetics
- Sponsors Sarepta Therapeutics
- 02 Aug 2012 Trial company changed from AVI BioPharma to Sarepta Therapeutics as reported by ClinicalTrials.gov.
- 20 Jul 2009 New trial record